Yttrium Y-90 Ibritumomab Tiuxetan

RADIATION3 trials

Sponsors

Mayo Clinic, Fred Hutchinson Cancer Center

Conditions

Adult Non-Hodgkin LymphomaAnn Arbor Stage I Grade 1 Follicular LymphomaAnn Arbor Stage I Grade 2 Follicular LymphomaAnn Arbor Stage II Grade 1 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 1 Non-Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Non-Contiguous Follicular LymphomaAnn Arbor Stage III Grade 1 Follicular Lymphoma

Phase 1

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

CompletedNCT00438880

Mayo ClinicAdult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma +9

Start: 2004-10-31End: 2014-11-30Updated: 2016-02-04

Phase 2

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

TerminatedNCT01434472

Fred Hutchinson Cancer CenterPost-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma +4

Start: 2011-11-16End: 2020-05-06Updated: 2021-07-20

Phase 3

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

TerminatedNCT02320292

Mayo ClinicAnn Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma +7

Start: 2015-02-11End: 2023-11-09Updated: 2025-07-09

Related Papers

Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Blood2019-11-136 citations